Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here

Drugs · Published 2026-02-23 · DOI 10.1007/s40265-026-02295-0

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1007/s40265-026-02295-0

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Sibeprenlimab: First Approval · Drugs · 2026 · Same journal
• The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir · Drugs · 2026 · Same journal
• Ecnoglutide: First Approvals · Drugs · 2026 · Same journal
• Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering · Drugs · 2026 · Same journal
• Etripamil: First Approval · Drugs · 2026 · Same journal
• Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections · Drugs · 2026 · Same journal
• Emerging Cardiorenal Protective Therapies in Lupus Nephritis · Drugs · 2026 · Same journal
• Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors · Drugs · 2026 · Same journal
• The Role of β-Blockers in the Evolving Treatment Landscape of Resistant Hypertension · Drugs · 2026 · Same journal
• Culmerciclib: First Approval · Drugs · 2026 · Same journal